The estimated Net Worth of D Keith Grossman is at least $15 Milion dollars as of 3 June 2024. Mr. Grossman owns over 69,303 units of Nevro Corp stock worth over $404,693 and over the last 21 years he sold NVRO stock worth over $715,648. In addition, he makes $13,877,700 as Chairman of the Board, President oraz Chief Executive Officer at Nevro Corp.
Sign up
Mr. Grossman NVRO stock SEC Form 4 insiders trading
D has made over 16 trades of the Nevro Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 69,303 units of NVRO stock worth $76,926 on 3 June 2024.
The largest trade he's ever made was exercising 69,303 units of Nevro Corp stock on 3 June 2024 worth over $76,926. On average, D trades about 1,155 units every 63 days since 2003. As of 3 June 2024 he still owns at least 85,922 units of Nevro Corp stock.
You can see the complete history of Mr. Grossman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
D.Keith Grossman biography
D.Keith Grossman is Chairman of the Board, President, Chief Executive Officer of the company. Mr. Grossman has over 30 years of experience in the medical device field. Mr. Grossman served most recently, and for the second time, as the President, Chief Executive Officer and director of Thoratec Corporation (“Thoratec”), leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, Chief Executive Officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of Texas Pacific Group (“TPG”), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Chairman of the Board of Outset Medical, Inc., a privately-held company, as Vice Chairman of Alcon, Inc., as a board member of ViewRay, Inc. and previously served as a member of the board of directors of Intuitive Surgical, Inc., Kyphon, Inc., Zeltiq and a number of privately-held medical device companies. Mr. Grossman received a B.S. in Animal Science from The Ohio State University and an M.B.A. from Pepperdine University.
What is the salary of D Grossman?
As the Chairman of the Board, President oraz Chief Executive Officer of Nevro Corp, the total compensation of D Grossman at Nevro Corp is $13,877,700. There are no executives at Nevro Corp getting paid more.
How old is D Grossman?
D Grossman is 59, he's been the Chairman of the Board, President oraz Chief Executive Officer of Nevro Corp since 2019. There are 14 older and 10 younger executives at Nevro Corp. The oldest executive at Nevro Corp is Frank Fischer, 78, who is the Independent Director.
What's D Grossman's mailing address?
D's mailing address filed with the SEC is C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY, CA, 94065.
Insiders trading at Nevro Corp
Over the last 10 years, insiders at Nevro Corp have traded over $298,472,982 worth of Nevro Corp stock and bought 312,708 units worth $8,709,518 . The most active insiders traders include Ali Behbahani, Holdings A/S Novo oraz & Johnson Johnson & Johnson.... On average, Nevro Corp executives and independent directors trade stock every 18 days with the average trade being worth of $161,002. The most recent stock trade was executed by Shawn Mc Cormick on 7 June 2023, trading 7,500 units of NVRO stock currently worth $171,600.
What does Nevro Corp do?
headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
What does Nevro Corp's logo look like?
Complete history of Mr. Grossman stock trades at Intuitive Surgical Inc, ViewRay, Nevro Corp oraz Outset Medical
Nevro Corp executives and stock owners
Nevro Corp executives and other stock owners filed with the SEC include:
-
D.Keith Grossman,
Chairman of the Board, President, Chief Executive Officer -
Niamh Pellegrini,
Chief Commercial Officer -
Michael Carter,
Vice President - Global Sales -
Christopher Christoforou,
Vice President - Research and Development -
D. Keith Grossman,
Chairman, CEO & Pres -
Patrick Schmitz,
Vice President - Operations -
Kashif Rashid,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Andrew H. Galligan,
Exec. Officer -
Kashif Rashid,
Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Roderick H. MacLeod,
Chief Financial Officer -
Elizabeth Weatherman,
Independent Director -
Kevin O'Boyle,
Independent Director -
Karen Prange,
Independent Director -
Michael DeMane,
Lead Independent Director -
Wilfred Jaeger,
Independent Director -
Shawn McCormick,
Independent Director -
Frank Fischer,
Independent Director -
Brad Vale,
Independent Director -
David Caraway,
Chief Medical Officer -
Donald Middlebrook,
Vice President - Clinical, Regulatory and Quality -
Juliet Cunningham,
Vice President - Investor Relations -
Lori Ciano,
Chief Human Resource Officer -
Roderick MacLeod,
Chief Financial Officer -
Dr. David Caraway,
Chief Medical Officer -
Lori M. Ciano,
Chief HR Officer -
Patrick Schmitz,
VP of Operations -
Jon R. Shear,
VP of Corp. Devel. -
Michael Collier Carter,
VP of Global Sales -
Julie D. Dewey,
Chief Corp. Communications & Investor Relations Officer -
Sridhar Kosaraju,
-
James Alecxih,
Vice President, Sales -
Lisa D Earnhardt,
Director -
Andre Walker,
Senior VP,Research&Development -
Ali Behbahani,
Director -
Kevin R Thornal,
President & CEO -
Rami Elghandour,
President -
Michael Enxing,
VP of Sales & Marketing -
Arch Management Iv, L.L.C.T...,
-
City Capital Llc Bay City C...,
-
Holdings A/S Novo,
10% owner -
Partners Ii Lp Amv,
-
City Capital Llc Bay City C...,
-
Nathan B Pliam,
Director -
& Johnson Johnson & Johnson...,
-
Balakrishnan Shankar,
VP, Operations -
Andrew H Galligan,
Chief Financial Officer -
Doug Alleavitch,
VP, Quality -
Kirt P Karros,
-
Christofer Christoforou,
SVP, Chief Operating Officer -
Greg Siller,
SVP & Chief Commercial Officer -
Richard B. Carter,
Chief Accounting Officer -
Susan E Siegel,